Fugitive42 (@fugitive4242) profile picture
Maine, USA
Joined January 2025
Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)Photo by Fugitive42 (@fugitive4242)
$IOVA Fred hit it out of the park! This company is a juggernaut! We don't have enough shares is the understatement of the year. Load up kids its trading with absolutely nothing priced in.
3
28
2,173
$IOVA The FDA’s focus should be improving the lives of cancer patients by replacing older, inferior modalities with superior therapies. Amtagvi has already demonstrated it can do that in melanoma. The LUN-202 data show the same advantage in lung cancer. Approving it is the logical next step. Why the FDA will approve lifileucel (LUN-202) for previously treated nonsquamous mNSCLC, it’s clearly better than what patients have now. The FDA already gave positive feedback on the IOV-LUN-202 trial design and potency assay matrix. Interim data show 26% ORR with mDOR not reached after 25+ months of follow up and the final 80 patient dataset is expected to hold that profile. Compare that to current standards after chemo plus immunotherapy: Docetaxel alone: 13% ORR, mDOR 5–6 months Docetaxel plus ramucirumab: 15–23% ORR, short lived responses Lifileucel is a one time treatment (not ongoing chemo), with disease control rate 70% and responses that are still ongoing years later. That’s a different quality of benefit. Even stronger in key subgroups: KRAS wild type: 43% ORR KRAS + HER2 wild type: 52% ORR Biomarker-enriched (KRAS/HER2 WT + ever-smoker): 59% ORR These patients have limited options and poor durability with existing drugs. A single infusion that delivers higher response rates and dramatically longer remissions addresses a real unmet need. The melanoma precedent (same product, similar single-arm ORR + mDOR NR) already set the bar, LUN-202 clears it. Patients deserve access while confirmatory work (including POSITILITY) continues.
2
37
1,129
$IOVA Real people. Real disease. Real hope. Real cures. Fourteen years after TIL therapy, some patients are still celebrating anniversaries. Others are just starting their journey day one in the hospital, holding hands, ready to fight. A year later, clean scans. A second clean PET. Messages of “You’ve got this” from people who’ve walked the same path. This is what TIL therapy looks like beyond the numbers: patients who were told their options were limited, now marking years of life they weren’t sure they’d have. One treatment. One shot. Lives continuing. The data shows consistency. The patients show what’s possible. The numbers matter. The people matter more.
3
38
1,116
$IOVA H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Brian Gastman: IOV-LUN-202 “We are not just moving silently alone, but we do have regular interaction with the FDA, and that led to our Fast Track designation. As we know, the unmet need is so large and the goal of getting this to patients as soon as possible is something that we and the FDA share together.”
32
1,237
Iovance lung data consistency Fast Track for lifileucel in 2L non squamous NSCLC was granted in February 2026 based on the clinical data available at the time (26% ORR, with mDOR not reached at 25+ months of follow up). The update just reported (Oct 2026) showed 24.6% ORR in 69 patients consistent with the prior result that supported the designation. Median duration of response remains not reached. On the recent earnings call, management noted there is a good chance mDOR will still not be reached at the time of the planned sBLA submission in 2027. This is not a situation where Fast Track was awarded years ago on different data. The overall unselected response rate and durability profile that earned the designation are essentially the same as what the company just presented, and they are advancing toward a planned sBLA in 2027. Management and the former FDA regulatory leadership at the company have stated they view the profile as approvable in this high unmet need setting.
1
17
788
$IOVA Stick this in your pipe and smoke it bears! Amtagvi becoming SOC in 2L melanoma Iovance says doctors are using it in rising numbers due to duration of response. US 2L+ advanced melanoma TAM: 8,500 pts/year. Current run-rate: 7-9% share (650-800 pts). >1,000 commercial patients treated since launch. At $710k total per pt (Amtagvi + Proleukin): 20% share of 8,500→ 1,700 pts → $1.2B US revenue 30% share of 8,500→ 2,550 pts → $1.8B US revenue Company already targets $1B+ peak US from advanced melanoma alone. Path to 20-30% rests on ATC/community expansion + sustained real world durability driving earlier use. The entire pipeline and its potential revenue are not priced in yet. Juggernaut is an understatement. Pipeline TAMs (company mins) Frontline melanoma: >2x current 2L (70k global addressable) Lung (biomarker-selected 1L+2L): 10x current 2L melanoma Sarcoma (UPS+DDLPS): 1x current 2L melanoma
1
38
3,832
$IOVA The $4–$15/$17.50 run priced in a clean, high conviction outcome. Once so many were sitting on large unrealized gains, the bar shifted from “is the thesis intact?” to “does this meet the perfect scenario?” Anything short of that especially a sudden lung presentation that didn’t deliver instant clarity became a hair trigger. People didn’t want to give back profits they were already mentally spending. That triggered the first wave of selling. The order book simply cannot absorb large, one sided flow without extreme price impact. In a name that had run that hard, liquidity thinned fast, stops got hit, and margin calls cascaded. The run up itself made no fundamental sense either; both the melt up and the collapse were driven more by positioning and psychology than by a measured reading of the company or the data. On paper I’m down well over $1 million in the past week. I’m not worried in the least about reclaiming that 3x. One speed bump on the Autobahn, then foot to the floor.
6
49
2,568
$IOVA Half the market cap gone from a rushed, muddy press conference on the lung data. Wayne showed up to announce he’s running things—so that presentation failure is on him. This is still a lump of coal. The technology, infrastructure, manufacturing capacity, ATC network, and patents underneath are the real assets. The pressure is on to turn it into diamonds and extract that value for shareholders. Tomorrow’s earnings isn’t optional. Bring the A-game: clear messaging, no more fog, and a roadmap that shows how this gets unlocked. The market punished the confusion. Now deliver the substance. I’m here until that value is realized. 💎
6
1
51
2,855
$IOVA Wells Fargo easy read. Company Update — October 29, 2026 Biotechnology Iovance Biotherapeutics Updated 2L mNSCLC Data with Promising Biomarker-Enrichment Strategy Our Call We note 59% ORR in KRAS WT/HER2 WT/ever-smokers strengthens TIL’s value proposition in 2L nsq-mNSCLC. Overall pop’s ORR held at 25%, mDOR was immature (~1 yr), and reduced LD led to improved safety, cutting Gr5 AE in half & cutting hosp. days >50%. We think today’s stock weakness could be due to concerns regarding durability and whether reduced lymphodepletion (LD) impacted DOR. We note if TIL expansion was impaired (from insufficient LD), ORR probably would have been impacted, which we note is not the case. We therefore expect mature DOR data to still be positive and clearing our experts’ bar of 12 months. With final data-cut expected in early ’27, we expect focus for the NSCLC program to rotate to FDA discussions and BLA filing.
40
1,801
$IOVA The November 2025 update was on 39 patients who already had a median of 25.4 months of follow-up (mDOR not reached). The October 2026 update added roughly 30 more patients, bringing the total to 69. Those newer patients have much shorter time on study, so they haven’t had the chance to show long duration yet. When you mix them in, the overall current look of the swimmer plot gets pulled shorter (Fred’s “about a year” comment on the immature data). The longer tails from the earlier patients are still in the plot, but the newer, shorter-followed responses drag the present visual median down until more time passes. That’s normal when you expand a dataset with recent enrollees. It will be 2 years mdor when data is mature. Talk about jumping the gun on selling shares! Idiots!
1
3
28
1,329
$IOVA Fred Vogt: "Right now, if you estimated from that swimmer's plot where we'd be, we'd be at about a year, but I need to stress that the data is immature and data is still coming in and that we would expect to grow over time, and there's some patients that are coming in right now, obviously, that are responding. You really can't assess durability at this stage until the data's finally done. We're also in the middle of IRC reads and a lot of other things that will affect the outcome." "We are confident that the product is durable, and we'll show durability comparable to what we would expect from TIL therapies. On the broader question of whether FDA would accept this filing, we think a 25% response rate durable with a one-time treatment in this population should be approvable, and we think the FDA should accept it and should go forward." This is why the November 2025 cut on the earlier 39 patients still showed mDOR not reached at 25.4 months of median follow-up, while the larger October 2026 cut (69 patients) currently looks shorter on the swimmer plot. The newer patients simply haven’t been followed long enough yet to match the duration already seen in the earlier group. Once the final data cutoff happens in early 2027 and more follow-up accrues on the full 80-patient set, the median can still lengthen if the ongoing responses continue. People dont understand how mdor works and sold today. LMFAO!
6
4
1
43
3,773
$IOVA Who you going to listen to? Scare mongers on X or from the horses mouth? Fred Vogt (Interim CEO and President, Iovance Biotherapeutics): We continue to move forward towards the sBLA submission in 2027, and we will have further updates along the way, including on our confirmatory trial plan. As I mentioned, we expect approximately 80 non-squamous, non-small cell lung cancer patients to be included in the final data set for the sBLA. Today's data update represents nearly all of the patients in the expected data package. Our internal teams are focused on preparing for the sBLA submission. Independent review committee assessments, FDA discussions, and other pre-submission activities, including confirmatory trial preparation, are also ongoing. We look forward to completing enrollment in Cohorts 1 and 2 shortly and are confident in the road ahead in previously treated non-squamous metastatic non-small cell lung cancer, which earned FDA's Fast Track designation on the strength of our clinical data and represents an area of high unmet medical need.
4
1
42
2,842
$IOVA Back to reality. 2L non-squamous NSCLC after PD-1 Current standard of care (docetaxel) • ORR: 13% • mDOR: 5.6 months Amtagvi (lifileucel) – IOV-LUN-202 • ORR: 24.6% (17/69) • mDOR: not reached at prior 25.4-month median follow-up • Ongoing responses past 2–4 years on the swimmer plot • Management today: currently looks 18+ months reasonable Roughly double the response rate and meaningfully longer durability so far, with a one-time treatment. Which would you take? Why would the FDA say no? Not happening. Sbla to be filed in 2027. Its a superior treatment!
2
1
51
2,024
Standard 2L chemo (docetaxel) in post-PD-1 non-squamous NSCLC has historically shown 13% ORR and mDOR of 5.6 months. Docetaxel + ramucirumab is a bit better on ORR in some post-ICI datasets but mDOR still typically lands in the 5–6 month range. For Amtagvi (lifileucel) in the IOV-LUN-202 lung trial, the prior interim update had mDOR not reached after 25.4 months of median follow-up. Today’s update says durability remains consistent with that; the new swimmer plot still shows ongoing responses (including some past 2+ years). Management noted the data are still immature and currently look closer to 18 months on the plot, with room for the median to lengthen with more follow-up. So vs the current approved 2L standard, even a 18 month mDOR would already be roughly triple, and the long tails visible in the deck go well beyond that. That’s the durability argument people are watching.
Replying to @Whoiswho53 @jfais20
I think ppl paying less attention on ORR now, the mdor is what ppl are worried
2
9
796
$IOVA The last 11 patients have a real but bounded impact. Holding the mid-20s ORR requires a response rate in this final group similar to what has already been seen. A cluster of non-responders pulls the final number into the low 20s and strengthens the case for leaning on the precision (POSITILITY) path; a few extra responses keeps the broader population story intact for the planned 2027 sBLA. The company will have the final cutoff and more mature durability data in early 2027 before the actual filing. If the remaining patients happen to be enriched for the KRAS wild-type / HER2 wild-type / ever-smoker subgroup (the one that has been driving most responses so far), the overall ORR can tick up even with a modest number of new responses. If they are mostly KRAS-mutant, the opposite happens. The final dataset will also have more follow-up. A lower ORR with longer, cleaner durability (or more ongoing responses) is still usable for accelerated approval in this setting; a higher ORR with short durability is less attractive. Management has already said duration data are still immature.
🤖 Made with AI
1
1
19
1,388
$IOVA HCW maintains $20 price target.
5
1
52
5,500
$IOVA What we might hear about today. The poster from ESMO supports expanding who is considered for TIL therapy beyond the narrow clinical/histologic checklist used in the registrational trial. Manufacturing itself reinvigorates the pTR cells. That opens the door to: Patients with more exhausted tumors Patients with Treg-high / checkpoint-resistant biology Potentially other histologies or lines of therapy that currently fall outside the trial criteria In other words, the pool of patients who could reasonably be offered lifileucel gets larger. This is the mechanism behind “potentially broadening the strategy”. Selecting for sufficient reinvigorated pTR content in the final product could push the ORR from the mid-20s into the 30s or low-to-mid 40s in that enriched group, provided the trend in the poster holds in the full dataset. Today’s webcast is the first chance to see whether they quantify this relationship (e.g., ORR by pTR tertile or a proposed cutoff).
6
1,186
$IOVA Market lost its mind over Moderna’s $MRNA personalized melanoma vaccine , still years from approval and only for a small subset of high risk resected patients (adjuvant recurrence prevention). Meanwhile Iovance is already commercial with TIL therapy in melanoma and has positive registrational lung data dropping tomorrow in previously treated nonsquamous mNSCLC. TAM there is massive (hundreds of thousands of addressable patients globally). Lung cancer has been a Phase 3 graveyard the last two years. A real win here should matter a lot more than another adjuvant melanoma story.
22
1,145
$IOVA Lung trial failures (last 2 years) AstraZeneca → volrustomig (NSCLC, PD-L1 low): Phase 3 eVOLVE-Lung02 stopped for futility; unlikely to beat Keytruda + chemo on PFS/OS (~Aug 2026). AstraZeneca → ceralasertib + Imfinzi (previously treated NSCLC): Phase 3 LATIFY missed OS vs docetaxel (~Dec 2025). Pfizer → sigvotatug vedotin (ADC, pretreated nonsquamous NSCLC): Phase 3 SigVie-002 missed OS vs docetaxel (~June 2026). Jazz / PharmaMar → Zepzelca (lurbinectedin, relapsed SCLC): Phase 3 LAGOON missed OS (mono and combo); led to withdrawal of second-line indication (~June 2026). Gilead / Merck → sacituzumab govitecan + Keytruda (1L PD-L1-high NSCLC): Phase 3 EVOKE-03/KEYNOTE-D46 missed PFS; no OS benefit; trial discontinued (~2026). Immutep → eftilagimod alfa + Keytruda + chemo (1L NSCLC): Phase 3 TACTI-004 stopped for futility (~March 2026). Merck / Daiichi → ifinatamab deruxtecan (I-DXd, relapsed SCLC): Withdrew accelerated approval filing (Phase 2 data insufficient); Phase 3 had partial hold for ILD deaths (~2025–2026). Merck / Daiichi → patritumab deruxtecan (HER3-DXd, EGFR-mutated NSCLC): Phase 3 HERTHENA-Lung02 missed OS; withdrew application (~2025). Roche → Tecentriq (periadjuvant NSCLC): Impower-030 failed primary EFS (non-significant due to design/stats) (~2026). These are the main high-profile Phase 3 primary-endpoint misses or early terminations in lung cancer from the period. Not every smaller or mid stage miss is included. Iovance steps to the plate.
1
1
1
32
2,858
$IOVA IOV-LUN-202 is an open-label, non-randomized, multi-cohort Phase 2 study. What that means for visibility: Iovance (and the investigators) can see safety data, manufacturing success rates, and investigator-assessed responses as they occur. The primary endpoint for the key registrational cohorts is still objective response rate by an independent review committee (IRC) using RECIST v1.1, which provides a layer of independent confirmation. Secondary endpoints (duration of response, disease control rate, PFS, OS, etc.) are also tracked over time, so durability trends become visible to the sponsor well before a formal data cut is locked and presented. Frederick (“Fred”) Vogt, Interim CEO, on the Q2 2026 earnings call (August 6, 2026 “The lung is looking very positive right now. We feel very good about where we stand with the study and we will have a lot, I think, to say about that. I know that’s a very key thing for investors and I really urge everybody to watch carefully as we talk about that, and maybe even more than what people are expecting in this space.” “We’re seeing very strong durability, I think very similar in overall outcome to what we saw in melanoma. It’s effectively the same type of product. When we get a response, it’s usually pretty durable.”
1
23
1,181